Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies
JCO Oncology Practice · 2023
DOI: 10.1200/op.22.00710 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JCO Oncology Practice, 2023. Verfasst von Asmi Chattaraj und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, UPMC McKeesport, McKeesport, PA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ototoxicity, Hearing Loss, Head and Neck Neoplasms. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Cisplatin is a bedrock of cancer management and one of the most used chemotherapeutic agents in the treatment of germ cell, lung, bladder, ovarian, and head and neck cancers. Approximately 500,000 patients diagnosed annually with these cancer types in the United States could be candidates for treatment with cisplatin. There is a 5-fold increase in the risk of hearing impairment or ototoxicity with cisplatin, which can manifest as ringing in the ear (tinnitus), high-frequency hearing loss, and at late stages, a decreased ability to hear normal conversation. More than half of adult and pediatric patients with cancer treated with cisplatin developed hearing impairment with major impact on patients' health-related quality of life. A considerable evidence gap persists regarding the burden and effective prevention and interception strategies for cisplatin-induced ototoxicity, especially in adult patients with cancer. We conducted a review of the published literature to provide an update on the status of this important clinical challenge. We also surveyed practicing oncologists within our network of academic and community practices to gain a better understanding of how the published literature compares with real-world practice. Our review of the literature showed a lack of standardized guidelines for monitoring and treatment of cisplatin-induced ototoxicity, especially in the adult cancer patient population. Our survey of practicing oncologists mirrored the findings from the published literature with a heterogeneity of practice, which highlights the need for standardization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, UPMC McKeesport, McKeesport, PA.
- Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
- UPMC Hillman Cancer Center, Pittsburgh, PA.
ORCID-Profile: Asmi Chattaraj, Masood Pasha Syed, Carissa A Low, Taofeek K Owonikoko
Förderung
- NCI NIH HHS
Zitieren
APA
Chattaraj, A., Syed, M. P., Low, C. A., & Owonikoko, T. K. (2023). Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies. JCO Oncology Practice. https://doi.org/10.1200/op.22.00710
Vancouver
Chattaraj A, Syed MP, Low CA, Owonikoko TK. Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies. JCO Oncology Practice. 2023. doi:10.1200/op.22.00710
BibTeX
@article{Chattaraj2023,
author = {Chattaraj, Asmi and Syed, Masood Pasha and Low, Carissa A and Owonikoko, Taofeek K},
title = {Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies},
journal = {JCO Oncology Practice},
year = {2023},
doi = {10.1200/op.22.00710}
}
EUVIMED